BridgeMD
Compares treatment options for Tendinopathy
Official title Efficacy of Therapeutic Percutaneous Electrolysis Simple vs Multifiliar Therapy in Supraspinatus Tendinopathy.
ClinicalTrials.gov ID: NCT07247825
What this study is testing
- What it's testing
- Supraspinatus tendinopathy (SE) is one of the main pathologies that cause functional alterations in the glenohumeral joint. It reduces the quality of life of the population suffering from this injury.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Signing of informed consent both to participate in the study and to undergo invasive physiotherapy techniques.
- Presence of symptoms (inflammation or pain) ≥ 4 weeks.
- Positive palpation test of the supraspinatus tendon.
- Men and women over 18 years of age.
- Score of 3 or higher on the shoulder pain analogue scale.
You likely can't join if
- Any related acute or chronic musculoskeletal disease that may affect the results of the study.
- Presence of neuropathic pain such as lumbar radiculopathy, which may affect the results of the study.
- Not receiving the treatment sessions and assessments of the study.
- History of glenohumeral fracture and rheumatoid arthritis.
- Rheumatic, neurological or structural polymyalgia affecting the joint.
- Pregnancy.
See the full eligibility criteria
- Signing of informed consent both to participate in the study and to undergo invasive physiotherapy techniques.
- Presence of symptoms (inflammation or pain) ≥ 4 weeks.
- Positive palpation test of the supraspinatus tendon.
- Men and women over 18 years of age.
- Score of 3 or higher on the shoulder pain analogue scale.
- Adequate cognitive ability for understanding.
- Limited range of motion.
- Rotator cuff tendinopathy confirmed by ultrasound at the study centre, either due to tendon inflammation, presence of hypoechoic areas, calcification, fibrillar disorganisation and/or neovascularisation in the...
- Pain in the proximal lateral part of the arm that worsens with abduction.
- Any related acute or chronic musculoskeletal disease that may affect the results of the study.
- Presence of neuropathic pain such as lumbar radiculopathy, which may affect the results of the study.
- Not receiving the treatment sessions and assessments of the study.
- History of glenohumeral fracture and rheumatoid arthritis.
- Rheumatic, neurological or structural polymyalgia affecting the joint.
- Pregnancy.
- Patients with cardiovascular disease.
- Patients with neurological disease.
- Local infection.
- Tumours.
- Belonephobia.
- Taking anticoagulants or antiplatelet agents.
- Infiltrative and/or rehabilitative treatment in the two months prior to recruitment.
- Treatment with another intervention during the study.
The study team makes the final eligibility decision.
Where it's taking place
- Salamanca, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Salamanca, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.